D.A. Davidson & CO. Purchases 28,410 Shares of Bristol Myers Squibb Company $BMY

D.A. Davidson & CO. lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 294,929 shares of the biopharmaceutical company's stock after purchasing an additional 28,410 shares during the period. D.A. Davidson & CO.'s holdings in Bristol Myers Squibb were worth $15,908,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Physician Wealth Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 202 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Bristol Myers Squibb during the third quarter valued at approximately $35,000. Finally, JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the third quarter valued at approximately $36,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $57.86 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock has a market cap of $118.13 billion, a PE ratio of 16.77, a PEG ratio of 0.17 and a beta of 0.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm's 50 day moving average price is $59.63 and its two-hundred day moving average price is $54.31.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the previous year, the business posted $1.67 earnings per share. Bristol Myers Squibb's revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is 73.04%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on BMY shares. Leerink Partners increased their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research note on Tuesday, January 13th. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research note on Tuesday, March 17th. Wells Fargo & Company reiterated an "outperform" rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Cantor Fitzgerald raised their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, April 8th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.